New Research: Diammonium Glycyrrhizinate Shows Promise

# New Research: Diammonium Glycyrrhizinate and Vitamin D3 Show Promise Against Pulmonary Fibrosis A groundbreaking new study published in the Journal of Ethnopharmacology has revealed promising findings about the combination of diammonium glycyrrhizinate (DG) and vitamin D3 in treating pulmonary fibrosis. While this research doesn't directly involve thymosin alpha 1 immune modulation, it provides important insights into novel therapeutic approaches for fibrotic diseases that could inform future peptide therapy development and immune system research. ## What This Study Found Researchers investigated the synergistic effects of diammonium glycyrrhizinate—a compound derived from traditional Chinese licorice (Glycyrrhiza spp.)—combined with vitamin D3 against pulmonary fibrosis. The study employed a comprehensive approach including network pharmacology, molecular docking, and animal models to understand the mechanisms involved. Key findings from the research include: - **Significant improvement in bleomycin-induced pulmonary fibrosis** in animal models when treated with the DG and vitamin D3 combination - **Reduced epithelial-mesenchymal transition (EMT)**, a critical process in fibrosis development, as evidenced by decreased N-Cadherin and α-SMA expression and increased E-Cadherin levels - **Identification of key molecular targets**: STAT3 and HSP90AA1 were identified as primary synergistic targets through network pharmacology analysis - **HIF-1α pathway modulation**: The combination treatment significantly decreased levels of STAT3, HSP90AA1, and HIF-1α proteins - **Crosstalk confirmation**: Silencing either STAT3 or HSP90AA1 demonstrated their mutual suppression and combined effect on the HIF-1α signaling pathway The study suggests that this combination therapy works by modulating the crosstalk between STAT3/HSP90AA1 and the HIF-1α pathway, leading to reduced fibrotic changes and improved tissue architecture. ## Clinical Significance This research holds significant implications for healthcare practitioners treating fibrotic diseases. Pulmonary fibrosis represents a challenging condition with limited treatment options, and the identification of novel therapeutic combinations could expand the treatment landscape. For practitioners interested in integrative approaches, the study demonstrates how traditional medicine compounds can be scientifically validated through modern research methodologies. The use of network pharmacology and molecular docking represents a sophisticated approach to understanding drug interactions and mechanisms. Importantly, while this study focused on diammonium glycyrrhizinate and vitamin D3, the identified pathways (particularly STAT3 and HIF-1α signaling) are also relevant to other therapeutic modalities. Understanding these mechanisms could inform treatment protocols involving other compounds that may have peptide therapy side effects or interact with immune-modulating treatments. The research methodology employed—combining computational predictions with both in vitro and in vivo validation—provides a robust framework that could be applied to other therapeutic investigations, including those involving peptides with immune-modulating properties. ## Current Access and Compliance Context Diammonium glycyrrhizinate is not currently classified as a peptide therapeutic, and therefore falls outside the typical 503A/503B compounding regulations that govern peptide therapies. However, this research highlights the importance of understanding regulatory pathways for novel therapeutic combinations. Vitamin D3, being a well-established supplement, is widely available, but practitioners should note that therapeutic dosing for specific conditions may require different considerations than standard supplementation protocols. The study does not specify exact dosing protocols used, emphasizing the need for further clinical research before therapeutic implementation. For practitioners working with peptide therapies, this research underscores the importance of understanding how different therapeutic modalities might interact with similar pathways. The STAT3 and HIF-1α pathways identified in this study are also relevant to various peptide-based treatments, particularly those with immune-modulating effects. Currently, there is no FDA approval for diammonium glycyrrhizinate as a treatment for pulmonary fibrosis in the United States, and this research represents preclinical findings that require further human clinical trials for validation. ## What Patients Should Know Patients interested in this research should understand that these findings come from laboratory and animal studies, not human clinical trials. While the results are promising, significant additional research is needed before this combination could be considered a viable treatment option for pulmonary fibrosis. The study focused on understanding how two compounds—one derived from licorice root and vitamin D3—might work together to reduce lung scarring. The researchers found that this combination appeared to help prevent cells from changing in ways that contribute to lung scarring, and it seemed to work by affecting specific cellular pathways. For patients currently managing pulmonary fibrosis or other fibrotic conditions, it's important to continue with established treatment protocols while staying informed about emerging research. This study adds to the growing body of evidence supporting the potential role of vitamin D3 in various health conditions, though therapeutic dosing should always be supervised by healthcare providers. Patients should also be aware that while natural compounds like those derived from licorice have been used traditionally, their interaction with conventional treatments and potential for thymosin alpha 1 cancer research applications or other peptide-based therapies requires professional medical evaluation. ## Conclusion This research represents an important step forward in understanding potential new approaches to treating pulmonary fibrosis through the combination of diammonium glycyrrhizinate and vitamin D3. The identification of specific molecular pathways and targets provides valuable insights that could inform future therapeutic development. While these findings are preliminary and require human clinical validation, they demonstrate the value of applying modern research methodologies to traditional medicine compounds. For healthcare providers interested in staying current with emerging therapeutic research, continued education and professional guidance remain essential. To connect with qualified healthcare providers who stay current with the latest research in peptide therapy and integrative medicine, visit [peptideassociation.org/find-a-doctor](https://peptideassociation.org/find-a-doctor). --- **Medical Disclaimer:** This article is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment recommendations. The research discussed represents preclinical findings that have not been validated in human clinical trials. Always consult with qualified healthcare providers before making any changes to your treatment regimen. Individual results may vary, and what works in laboratory or animal studies may not translate to human applications. **Source Citation:** Shen Y, Li X, et al. Synergistic effects of diammonium glycyrrhizinate and vitamin D3 against EMT in pulmonary fibrosis through modulating the crosstalk of STAT3/HSP90AA1 and HIF-1α pathway. *J Ethnopharmacol*. 2026;25:120649. doi:10.1016/j.jep.2025.120649